Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Market price (% of par)
-
95.33%
-
Total 13F principal
-
$832,977,781
-
Principal change
-
+$9,503,274
-
Total reported market value
-
$795,652,096
-
Number of holders
-
57
-
Value change
-
+$12,847,172
-
Number of buys
-
19
-
Number of sells
-
26
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q2 2024
As of 30 Jun 2024,
HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 was held by
57 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$832,977,781
in principal (par value) of the bond.
The largest 10 bondholders included
Voya Investment Management LLC, Linden Advisors LP, CAMDEN ASSET MANAGEMENT L P /CA, Invesco Ltd., Wellesley Asset Management, Davidson Kempner Capital Management LP, LAZARD ASSET MANAGEMENT LLC, BlackRock Inc., III Capital Management, and AVIVA PLC.
This page lists
58
institutional bondholders reporting positions
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.